Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

As HIV-infected adults on successful antiretroviral therapy (ART) are expected to have close to normal lifespans, they will increasingly develop age-related comorbidities. The objective of this cross-sectional study was to compare in the French Dat’AIDS cohort, the HIV geriatric population, aged 75 years and over, to the elderly one, aged from 50 to 74 years. As of Dec 2015, 16,436 subjects (43.8% of the French Dat’AIDS cohort) were aged from 50 to 74 (elderly group) and 572 subjects (1.5%) were aged 75 and over (geriatric group). Durations of HIV infection and of ART were slightly but significantly different, median at 19 and 18 years, and 15 and 16 years in the elderly and geriatric group, respectively. The geriatric group was more frequently at CDC stage C and had a lower nadir CD4. This group had been more exposed to first generation protease inhibitors and thymidine analogues. Despite similar virologic suppression, type of ART at the last visit significantly differed between the 2 groups: triple ART in 74% versus 68.2%, ART ≥ 4 drugs in 4.7% versus 2.7%; dual therapy in 11.6% versus 16.4% in the elderly group and the geriatric group, respectively. In the geriatric group all co-morbidities were significantly more frequent, except dyslipidemia, 4.3% of the elderly group had ≥4 co-morbidities versus18.4% in the geriatric group. Despite more co-morbidities and more advanced HIV infection the geriatric population achieve similar high rate of virologic suppression than the elderly population. A multidisciplinary approach should be developed to face the incoming challenge of aging HIV population.

[1]  G. Guaraldi,et al.  Geriatric-HIV Medicine Is Born. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Siegler,et al.  From One Syndrome to Many: Incorporating Geriatric Consultation Into HIV Care , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Katlama,et al.  Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study , 2017, HIV medicine.

[4]  M. Guiguet,et al.  Impact of age on care pathways of people living with HIV followed up in hospital , 2017, AIDS care.

[5]  G. Rahav,et al.  Missed opportunities for earlier diagnosis of HIV in patients who presented with advanced HIV disease: a retrospective cohort study , 2016, BMJ Open.

[6]  P. Reiss,et al.  Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  L. Cuzin,et al.  Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era — Role of chronic renal disease , 2016, The journal of nutrition, health & aging.

[8]  C. Larsen,et al.  Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study , 2016, Journal of acquired immune deficiency syndromes.

[9]  R. Hogg,et al.  Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada , 2015, BMC Infectious Diseases.

[10]  T. Hallett,et al.  Future challenges for clinical care of an ageing population infected with HIV: a modelling study , 2015, The Lancet. Infectious diseases.

[11]  J. Margolick,et al.  The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation , 2015, AIDS.

[12]  S. Gange,et al.  Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  P. Reiss,et al.  Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Landay,et al.  Is HIV a model of accelerated or accentuated aging? , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  C. Katlama,et al.  Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. , 2014, The Journal of antimicrobial chemotherapy.

[16]  V. Valcour,et al.  Polypharmacy, Drug–Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection , 2014, Journal of the American Geriatrics Society.

[17]  L. Goodall,et al.  Late diagnosis among our ageing HIV population: a cohort study , 2014, Journal of the International AIDS Society.

[18]  A. Royuela,et al.  Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio , 2014, PloS one.

[19]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[20]  P. Muret,et al.  Nevirapine–Raltegravir Combination, An Nrti and Pi/R Sparing Regimen, as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients , 2013, Antiviral therapy.

[21]  R. Ellis,et al.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection , 2013, AIDS.

[22]  H. van den Bussche,et al.  The influence of age, gender and socio-economic status on multimorbidity patterns in primary care. first results from the multicare cohort study , 2012, BMC Health Services Research.

[23]  A. Roverato,et al.  Premature age-related comorbidities among HIV-infected persons compared with the general population. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  S. Deeks,et al.  HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.

[25]  J. Hanlon,et al.  Managing medications in clinically complex elders: "There's got to be a happy medium". , 2010, JAMA.

[26]  R. Bosch,et al.  Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy , 2010, Diabetes Care.

[27]  L. Kuller,et al.  Lipoprotein particle subclasses, cardiovascular disease and HIV infection. , 2009, Atherosclerosis.

[28]  S. Cole,et al.  A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals , 2009, Journal of acquired immune deficiency syndromes.

[29]  L. Cuzin,et al.  A large French prospective cohort of HIV‐infected patients: the Nadis Cohort , 2009, HIV medicine.

[30]  A. Phillips,et al.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.

[31]  A. d’Arminio Monforte,et al.  Response to combination antiretroviral therapy: variation by age , 2008, AIDS.

[32]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[33]  Joseph T. Hanlon,et al.  Managing Medications in Clinically Complex Elders , 2016 .